Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10106190 | 0.89 | FDFT1 (0.53) | FDFT1LTA4HCETP | |
| SCHEMBL10272416 | 0.88 | FDFT1 (0.49) | FDFT1TSHRHSD17B10ALDH1A1KDM4E | |
| SCHEMBL25381878 | 0.88 | FDFT1 (0.57) | FDFT1TSHRHSD17B10ALDH1A1KDM4E | |
| SCHEMBL26218121 | 0.88 | TAAR1 (0.50) | FDFT1TSHRHSD17B10ALDH1A1KDM4E | |
| SCHEMBL8429859 | 0.86 | FDFT1 (0.46) | FDFT1LTA4HEPHX2TSHRHSD17B10 | |
| SCHEMBL1696397 | 0.86 | KDM4E (0.55) | FDFT1LTA4HTSHRHSD17B10ALDH1A1 | |
| SCHEMBL14127822 | 0.85 | FFAR1 (0.52) | FDFT1TSHRHSD17B10ALDH1A1KDM4E | |
| Ammonia Solution, Strong SCHEMBL27879510 | 0.84 | KDM4E (0.54) | FDFT1LTA4HTSHRHSD17B10ALDH1A1 | |
| SCHEMBL21770981 | 0.84 | KDM4E (0.54) | FDFT1LTA4HTSHRHSD17B10ALDH1A1 | |
| SCHEMBL15177141 | 0.83 | FDFT1 (0.45) | FDFT1LTA4HEPHX2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518000-B2 | Bicyclo [2.2.1] acid GPR120 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160016880-A1 | BICYCLO [2.2.1] ACID GPR120 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-21 | — | — | US | disclosed |
| US-8148367-B2 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-03 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016880-A1 | BICYCLO [2.2.1] ACID GPR120 MODULATORS | GPR180, GPR88, GPBAR1 | FDFT1 2633/4885LTA4H 1410/4885EPHX2 1748/4885 |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | FDFT1 2060/4885LTA4H 2450/4885EPHX2 2952/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | FDFT1 3194/4885LTA4H 1644/4885EPHX2 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.